Teijin Pharma Ltd. and NovAliX SAS have entered into a multi-target drug discovery collaboration to develop novel drug candidates against multiple targets across different therapeutic areas. NovAliX will initially use its protein biochemistry expertise and technology platforms to identify chemotypes, and then use its native nano-MS technology for further characterization of selected small molecule hit structures. NovAliX will receive technology access fees as well as further research funding. Financial details were not disclosed.

Stephan Jenn, president of NovAliX, said, “We are confident that this alliance will be very productive and are proud to be associated with Teijin’s technology-driven team. For NovAliX this integrated collaboration represents a significant milestone, as Teijin is the second Japanese pharmaceutical company to partner with us this year. This alliance underlines again the competitive edge of our scientific expertise and biophysical technologies as well as our commitment to serve the Japanese pharmaceutical research market that is strongly driven by science and innovation.”